Mode
Text Size
Log in / Sign up
N/A N=1,049 Randomized Health Services Research

A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease

Diabetes Mellitus, Type 2 · Cardiovascular Diseases

Enrolled (actual)
1,049
Serious AEs
0.3%
Results posted
Nov 2024
Primary outcome: Primary: Number of Participants Prescribed All 3 Groups of Recommended Evidence-based Medications — 173; 85 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Intense Education Intervention (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Dec 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Prescribed All 3 Groups of Recommended Evidence-based Medications
173; 85
SECONDARY
Number of Participants on Guideline Recommended Therapies at Last Follow-up Visit.
323; 334; 372; 402; 276; 209
SECONDARY
Change in Average LDL-C From Baseline to Last Follow-up Visit.
72.93; 75.07; 68.79; 70.60
SECONDARY
Number of Participants With LDL-C < 70 mg/dL
131; 111; 147; 126
SECONDARY
Change in Average Blood Pressure From Baseline to Last Follow-up Visit.
131.40; 129.47; 129.09; 130.35; 74.04; 72.35
SECONDARY
Number of Participants With sBP < 130 mmHg
185; 243; 200; 252
SECONDARY
Number of Participants With dBP < 180 mmHg
271; 348; 267; 355
SECONDARY
Change in Average HbA1c From Baseline to Last Follow-up Visit.
7.64; 7.50; 7.47; 7.49
SECONDARY
Number of Participants With HbA1c < 7%
181; 169; 197; 167
SECONDARY
Number of Participants Experiencing an Event Within 1 Year
23; 40; 6; 16; 3; 3

Summary

COORDINATE-Diabetes is a cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level educational intervention to improve the management of patients with type 2 diabetes mellitus and cardiovascular disease.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years old
  • Diagnosis of Type 2 diabetes mellitus (T2DM)
  • History of at least one of the following conditions:
  • Coronary artery disease (defined as prior MI, coronary revascularization (CABG or PCI), and/or obstructive CAD (≥50%) as documented by angiography or CTA)
  • Stroke and/or carotid artery stenosis (≥50%)
  • Peripheral Arterial disease (defined as claudication with ABI<0.9, prior peripheral revascularization, and/or amputation due to circulatory insufficiency)
  • Ability to communicate with site staff and understand and provide written informed consent and proof of Health Insurance Portability and Accountability Act (HIPAA) authorization

Exclusion Criteria

  • Determined to be highly unlikely to survive and/or to continue follow-up in that clinic for at least 1 year, as identified by site investigator
  • GFR<30 mL/min/1.73m2
  • Already on all guideline-recommended therapies for T2DM and CVD
  • Absolute contraindication to any of the guideline recommended therapies for T2DM and CVD
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03936660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search